You are here

Empowering the health evolution

10 May 2022
Healthcare

Bioiberica unveils DAOgest and Dermial® for the first time at Vitafoods 2022. 

Bioiberica today announces the launch of two additions to its branded ingredients portfolio DAOgest and Dermial® for digestive health and skin & beauty respectively. The company is also marking the event by spotlighting new delivery formats for its Collavant n2 native (undenatured) type II collagen ingredient for joint health. Unveiled at Vitafoods Europe 2022, the launches form part of Bioiberica’s mission to empower nutraceutical brands to innovate in the evolving healthcare market by creating future-facing solutions for the growing skin and beauty, digestive and joint health categories.

 

Making histamine intolerance history

Histamine intolerance affects an estimated 1-3% of the global population, causing them to experience allergy-like symptoms after consuming histamine rich foods,” comments Jaume Reguant, Healthcare Director at Bioiberica.

Until now, the market opportunities around this condition have remained largely unmet. That’s why Bioiberica developed DAOgest – a digestive health supplement ingredient, which provides diamine oxidase (DAO) enzyme to improve histamine digestion. A natural extract, the solution can provide an immediate effect at a low dose of 4.2 mg/serving.

Reguant continues: “We’re calling on our industry partners to join forces with us in our goal to develop long-term health solutions that will improve lives for generations to come. With DAOgest, we’re giving manufacturers the opportunity to do just that – to create finished dosage forms that have the power to enable those suffering with this digestive condition to enjoy their favourite foods and drinks.”

Nourishing innovation in skin and beauty

The nutricosmetics market is witnessing exponential growth, with today’s health-conscious consumers seeking exciting solutions that support beauty-from-within. For formulators exploring new product developments in this space, Bioiberica introduces Dermial® – the first hyaluronic acid matrix ingredient of its kind. Designed to power innovation in dietary supplements, functional foods and nutricosmetics, it is easy to formulate at a low daily dose (60 mg) and exhibits excellent organoleptic properties.

Harnessing Bioiberica’s decades of scientific research and expertise in glycosaminoglycans, Dermial® contains a combination of three naturally-occurring components – hyaluronic acid, glycosaminoglycans (including dermatan and chondroitin sulfate) and hydrolysed collagen. Together, they work in synergy to enable the development of cutting-edge products that nourish, hydrate and replenish the skin. Demonstrated by scientific studies, this unique composition has been shown to elicit superior results when compared to microbial fermentation origin hyaluronic acid, including increased in vitro production of type I collagen by 48%.

 

Driving collagen NPD in new delivery formats and functional foods

In addition, Bioiberica is highlighting its ability to further power innovation in the mobility space, through the unveiling of new delivery formats offering for its popular native (undenatured) type II collagen for joint health – Collavant n2.

Consumers are increasingly opting for formats beyond pills, capsules and softgels – including gummies and functional products – to help them meet specific health and nutrition goals. Gummy solutions, especially, are becoming a preferred format for many. With a reported 75% growth in 2021, they now have the largest non-pill market share at 21.3%,adds Reguant.

Formulators can therefore use this next generation collagen ingredient to develop appealing applications in the nutrition space, including gummies, sports powders and ready-to-drink shakes.

 

Health solutions fit for the future

Speaking about Bioiberica Healthcare’s long-term ambitions, Reguant, explains: “The world of healthcare is evolving at pace. And with demand at an all-time high, the nutraceutical industry is perfectly positioned to be at the forefront of discovery. But for manufacturers to succeed, they need to keep up with what really matters to consumers.

That’s where Bioiberica comes in. With the launch of DAOgest and Dermial®, our aim is to empower companies to take advantage of the innovation opportunities in growing and emerging health areas – so they’re not just keeping up with the health evolution, but driving it. Supported by our long-standing expertise in biologically-derived ingredients, our partners can create cutting-edge formulations that meet consumer needs both now, and in years to come.”

 

Related News

11 Mar 2022
Healthcare

Formulated with Bioiberica’s Collavant n2, Highflex type II collagen tablets meet unmet consumer needs for innovative, low dose joint health solutions in China.